enGene Holdings (ENGN) Stock Analysis & Winston Score

enGene Holdings is a small biotechnology company focused on developing gene therapy treatments for bladder cancer. It uses a technology platform called D-Linux to deliver genetic material directly into cells lining the bladder, without needing to alter the patient's DNA permanently. The company's main customers would be cancer patients and the hospitals or clinics that treat them. enGene makes no revenue yet, which is typical for early-stage biotech companies that are still running clinical trials. It operates primarily in North America and is a very small company with a market cap around $100 million. Its main competitive edge is its proprietary D-Linux delivery platform, which it claims can target bladder tissue more precisely than older methods. The biggest risk the company faces is clinical and financial — it must prove its treatments work in trials while continuing to spend cash it does not yet earn back, meaning it may need to raise more money from investors to survive.